Online citations, reference lists, and bibliographies.
← Back to Search

Analysis Of The Pathologic Response To Primary Chemotherapy In Patients With Locally Advanced Breast Cancer Grouped According To Estrogen Receptor, Progesterone Receptor, And HER2 Status.

L. Fernández-Morales, M. Seguí, X. Andreu, E. Dalmau, A. Sáez, C. Pericay, Cristina Santos, J. Montesinos, E. Gallardo, A. Arcusa, E. Saigí
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE In clinical practice, it is possible to classify breast tumors according to estrogen receptor (ER), progesterone receptor (PgR), and HER2 overexpression: ER negative, PgR negative, and HER2 overexpressing; ER negative, PgR negative, and HER2 negative; ER positive, PgR positive, and HER2 negative; ER positive, PgR positive, and HER2 overexpressing; and the less frequent remaining 4 combinations. The aim of this study was to determine the percentage of pathologic complete response (pCR) in patients with locally advanced breast cancer (LABC) treated with neoadjuvant or primary chemotherapy with anthracyclines and taxanes grouped according to ER, PgR, and HER2 status. PATIENTS AND METHODS Patients with LABC treated with primary chemotherapy including anthracyclines and taxanes were grouped according to ER, PgR, and HER2 status; pCR rates were analyzed using the chi(2) test; and correlations with a P value of < or = 0.05 were considered statistically significant. RESULTS A total of 103 patients were treated. Only 100 patients were included for the analysis of pCR. Eighteen patients exhibited pCR. The pCR rate for each subgroup was as follows: 39.1% (9 of 23) had ER-negative, PgR-negative, and HER2-negative disease (P < 0.01); 35.7% (5 of 14) had ER-negative, PgR-negative, and HER2-overexpressing disease; 33.3% (3 of 9) had ER-positive, PgR-positive, and HER2-overexpressing disease; and 2.8% (1 of 36) had ER-positive, PgR-positive, and HER2-negative disease (P < 0.01). CONCLUSION In patients with LABC, grouping breast tumors according to ER, PgR, and HER2 status can help predict pCR to primary chemotherapy.
This paper references
10.1016/0277-5379(82)90135-3
Oestrogen receptors, clinical features and prognosis in stage III breast cancer.
J. Stewart (1982)
10.1200/JCO.1999.17.2.460
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H. Kuerer (1999)
10.1056/NEJMP058197
The distinctive nature of HER2-positive breast cancers.
H. Burstein (2005)
10.1158/1078-0432.CCR-04-0380
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors
M. Colleoni (2004)
10.1001/JAMA.295.21.2492
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
L. Carey (2006)
10.1200/JCO.2005.08.955
Radiation therapy and tamoxifen: concurrent or sequential? That is the question.
T. Whelan (2005)
10.1038/sj.bjc.6600749
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
I. F. Faneyte (2003)
10.1007/978-0-387-88443-1
AJCC cancer staging handbook
F. L. Greene (2002)
10.1200/JCO.2005.02.6914
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
V. Guarneri (2006)
10.1016/S0889-8588(05)70065-4
Locally Advanced Breast Cancer.
Valero (1996)
10.1073/pnas.0932692100
Repeated observation of breast tumor subtypes in independent gene expression data sets
T. Sørlie (2003)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1002/cncr.11603
Neoadjuvant chemotherapy for breast carcinoma
T. Buchholz (2003)
10.1073/pnas.1732912100
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C. Sotiriou (2003)
10.1016/0002-9378(57)90180-1
Diseases of the Breast
C. Haagensen (1971)
10.1093/AJCP/78.6.806
The World Health Organization Histological Typing of Breast Tumors—Second Edition
J. Azzopardi (1982)
10.1016/S0360-3016(02)02850-X
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
T. Buchholz (2002)
10.1200/JCO.20.6.1456
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
I. C. Smith (2002)
10.1634/THEONCOLOGIST.8-6-521
Update on locally advanced breast cancer.
S. Giordano (2003)
Treatment of locally advanced breast cancer.
D. Booser (1992)
10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
C. Carter (1989)
10.1200/JCO.2005.07.032
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
10.1200/JCO.2003.12.005
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
H. Bear (2003)
10.1200/JCO.1997.15.7.2483
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B. Fisher (1997)
Pathological response to neoadjuvant chemotherapy Final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification
F. P. Llorca (1999)



This paper is referenced by
10.1177/0284185117705010
Agreement between MRI and pathologic analyses for determination of tumor size and correlation with immunohistochemical factors of invasive breast carcinoma
E. Y. Yoo (2018)
10.1016/J.ENFCLI.2009.12.002
Trayectoria clínica para mujer con cáncer de mama localmente avanzado en tratamiento con quimioterapia neoadyuvante
Mercè Mesalles-Sin (2010)
Significant elevation of CLDN 16 and HAPLN 3 gene expression in human breast cancer
Shou-Jen Kuo ()
10.5812/IRANJRADIOL.41928
HER2-Positive Breast Cancer: Tumor-to-Liver SUV Ratio is the Best Parameter for Detection in F-18 FDG-PET/CT
Yoshifumi Noda (2017)
10.1016/j.critrevonc.2018.09.012
Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapy.
P. Taourel (2018)
10.1371/journal.pone.0145390
The Values of Combined and Sub-Stratified Imaging Scores with Ultrasonography and Mammography in Breast Cancer Subtypes
Tsun-Hou Chang (2015)
Implicaciones clínicas y factores predictivo-pronósticos de la quimioterapia primaria en el cáncer de mama localmente avanzado
F. Morales (2016)
10.1007/s12094-013-1006-4
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
P. Sánchez-Rovira (2013)
10.1148/radiol.14140594
Can breast cancer molecular subtype help to select patients for preoperative MR imaging?
L. Grimm (2015)
10.1007/174_2014_1043
Biological Subtypes of Breast Cancer
Sara E. Barnato (2015)
10.1016/j.ejso.2009.01.014
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
R. Greil (2009)
10.1016/j.acra.2019.07.011
Dynamic Contrast-Enhanced MRI Evaluation of Pathologic Complete Response in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After HER2-Targeted Therapy.
Laura Heacock (2019)
10.1093/annonc/mdq406
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
H. Wildiers (2011)
Invasive Lobular Carcinoma : MRI Features and Clinicohistological Characteristics According to the ER , PR , and HER 2 Statuses
Eun Young Yoo (2015)
10.2967/jnumed.108.057281
Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
M. Dunphy (2009)
10.1007/978-3-319-43504-6_17
Use Case III: Imaging Biomarkers in Breast Tumours. Development and Clinical Integration
Maria Adele Marino (2017)
can Breast cancer Molecular s ubtype help to s elect Patients for Preoperative M
Lars J. Grimm (2015)
10.1016/j.semradonc.2009.05.004
Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
K. Huber (2009)
10.1002/jmri.25116
Breast MRI radiogenomics: Current status and research implications
L. Grimm (2016)
10.1148/radiol.14132641
Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.
M. Mazurowski (2014)
10.1002/jmri.24879
Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms
L. Grimm (2015)
10.1158/1078-0432.CCR-07-4557
Methylated NEUROD1 Promoter is a Marker for Chemosensitivity in Breast Cancer
H. Fiegl (2008)
10.1159/000330766
Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy
Serkan Keskin (2011)
10.1007/s10147-014-0727-x
Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice
J. Gavilá (2014)
10.1016/S1043-321X(07)80435-8
Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
C. Osborne (2008)
10.13104/IMRI.2015.19.3.137
Invasive Lobular Carcinoma: MRI Features and Clinicohistological Characteristics According to the ER, PR, and HER2 Statuses
E. Y. Yoo (2015)
SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer.
D. Chen (2010)
10.1007/s15013-014-0368-1
Neoadjuvante Therapieoptionen
Cornelia Liedtke (2014)
10.1016/j.ejso.2019.01.012
Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
Marissa L G Vane (2019)
10.1002/jcla.21682
Association of Novel Gene Polymorphisms RRM1 −756T>C and −269 C>A With Breast Cancer
D. Chen (2014)
Semantic Scholar Logo Some data provided by SemanticScholar